Daily Bulletin

Men's Weekly

.

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Chromatin Bioscience Signs Collaboration Agreement with Astellas

EDINBURGH, Scotland, April 14, 2025 /PRNewswire/ -- Chromatin Bioscience, a leader in the design of synthetic promoters and gene control systems, is pleased to announce a collaboration agreement with Astellas Pharma, a global life sciences company.

Under the agreement, Chromatin Bioscience will use its proprietary chromatinLENS platform to design cell-selective synthetic promoters aligned with Astellas' target profile. The designed promoters are expected to enable highly precise and durable gene expression in specific cell types.

"We're excited to begin this collaboration with Astellas," said Michael Roberts, CEO and Founder of Chromatin Bioscience. "We believe the ability to precisely control targeted gene expression is becoming increasingly critical across diverse applications in biotechnology. This collaboration reflects the growing interest in synthetic promoter technology as a key enabler in the development of precision-targeted biological systems."

Chromatin Bioscience's chromatinLENS platform enables the identification of gene regulatory elements from the dark genome and the rational design of synthetic promoters tailored to specific applications. The platform can be applied across a range of sectors—including therapeutics, agritech, industrial biotechnology, and bioprocessing. The collaboration with Astellas further validates the potential of the chromatinLENS platform and represents the latest milestone in a series of collaborations that are shaping Chromatin's continued growth and impact.

For more information about Chromatin Bio's recent collaborations, visit https://www.chromatinbio.com/news

Notes to Editors

About Chromatin BioscienceChromatin Bioscience is a biotechnology company focused on the design and development of synthetic promoters for targeted gene control systems. Its proprietary platform enables precise, cell-type-selective, and durable gene expression, which is key to advancing the next generation of therapeutics, bioproduction systems and agritech innovations. Chromatin's synthetic promoters have been integral to a growing number of client programs. For more information, visit www.chromatinbio.com.

 

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/4659283_AE59283_0

Business News

The Marketing Strategy That’s Quietly Draining Sydney Business Owners’ Bank Accounts

Sydney businesses are investing more in digital marketing than ever before. The intention is clear. More visibility should mean more leads, more customers, and steady growth. However, many business ...

Daily Bulletin - avatar Daily Bulletin

Why Mining Hose Solutions Are Essential For High-Performance Industrial Operations

In environments where the ground itself is constantly shifting, breaking, and being reshaped, every component must be built to endure. Mining operations are among the most demanding in the industria...

Daily Bulletin - avatar Daily Bulletin

The Reason Talented Teams Underperform

If you’re in business, you might have seen it before. A team of capable and smart people just suddenly slows down, and things start spiraling out of control. On paper, everything looks perfect, but ...

Daily Bulletin - avatar Daily Bulletin